tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

CGEM Stock Latest News

Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
Press ReleasesCullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
12h ago
CGEM
Cullinan Therapeutics price target raised to $30 from $20 at BTIG
PremiumThe Fly
Cullinan Therapeutics price target raised to $30 from $20 at BTIG
8d ago
CGEM
Cullinan Oncology price target lowered to $29 from $34 at H.C. Wainwright
PremiumThe Fly
Cullinan Oncology price target lowered to $29 from $34 at H.C. Wainwright
8d ago
CGEM
Cullinan Management’s Strategic Shift and Capital Raise
PremiumCompany Announcements
Cullinan Management’s Strategic Shift and Capital Raise
9d ago
8K
CGEM
Cullinan Oncology changes name to Cullinan Therapeutics
PremiumThe Fly
Cullinan Oncology changes name to Cullinan Therapeutics
9d ago
CGEM
Cullinan Oncology announces strategic expansion into autoimmune diseases
PremiumThe FlyCullinan Oncology announces strategic expansion into autoimmune diseases
9d ago
CGEM
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
PremiumPress Releases
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
9d ago
CGEM
Cullinan Therapeutics announces oversubscribed $280M private placement
PremiumThe Fly
Cullinan Therapeutics announces oversubscribed $280M private placement
9d ago
CGEM
Cullinan initiated with Outperform on oncology portfolio at William Blair
PremiumThe Fly
Cullinan initiated with Outperform on oncology portfolio at William Blair
10d ago
CGEM
Cullinan Oncology initiated with an Outperform at William Blair
PremiumThe Fly
Cullinan Oncology initiated with an Outperform at William Blair
10d ago
CGEM
Cullinan Management’s Capital Dilemma: Balancing Equity, Debt, and Partnerships to Avoid Dilution and Restrictions
PremiumCompany Announcements
Cullinan Management’s Capital Dilemma: Balancing Equity, Debt, and Partnerships to Avoid Dilution and Restrictions
1M ago
CGEM
Cullinan Oncology announces departure of CFO Jeff Trigilio
PremiumThe Fly
Cullinan Oncology announces departure of CFO Jeff Trigilio
1M ago
CGEM
Cullinan Oncology expects cash to provide runway into 2H26
PremiumThe FlyCullinan Oncology expects cash to provide runway into 2H26
1M ago
CGEM
Cullinan Oncology reports Q4 EPS (54c), consensus (96c)
PremiumThe Fly
Cullinan Oncology reports Q4 EPS (54c), consensus (96c)
1M ago
CGEM
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
PremiumPress Releases
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
1M ago
CGEM
CGEM Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
CGEM Upcoming Earnings Report: What to Expect?
2M ago
CGEM
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
PremiumPress Releases
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
2M ago
CGEM
Cullinan Oncology announces U.S. FDA clearance of IND for CLN-619
PremiumThe Fly
Cullinan Oncology announces U.S. FDA clearance of IND for CLN-619
2M ago
CGEM
Wedbush bullish on Cullinan Oncology, initiates with an Outperform
PremiumThe Fly
Wedbush bullish on Cullinan Oncology, initiates with an Outperform
2M ago
CGEM
Cullinan Oncology initiated with an Outperform at Wedbush
PremiumThe FlyCullinan Oncology initiated with an Outperform at Wedbush
2M ago
CGEM
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PremiumPress Releases
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
4M ago
CGEM
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
PremiumPress Releases
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
4M ago
CGEM

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >